ID

31567

Description

A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00642018

Link

https://clinicaltrials.gov/show/NCT00642018

Keywords

Versions (1)
  1. 9/5/18 9/5/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

September 5, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Prostate Cancer NCT00642018

English

Eligibility Prostate Cancer NCT00642018

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically or cytologically confirmed adenocarcinoma of the prostate which is metastatic and/or unresectable
Description

Adenocarcinoma of the prostate metastatic | Adenocarcinoma of prostate unresectable

Data type

boolean

Alias
UMLS CUI [1]
C0862636
UMLS CUI [2,1]
C0007112
UMLS CUI [2,2]
C1519810
hormone refractory prostate cancer defined as progressive based by documented 2 increase psa values over a previous reference value.
Description

Hormone refractory prostate cancer Progressive | Raised prostate specific antigen Quantity

Data type

boolean

Alias
UMLS CUI [1,1]
C1328504
UMLS CUI [1,2]
C0205329
UMLS CUI [2,1]
C0178415
UMLS CUI [2,2]
C1265611
ecog status 0-2
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
adequate hematological functions, liver and renal functions
Description

Hematologic function | Liver function | Renal function

Data type

boolean

Alias
UMLS CUI [1]
C0221130
UMLS CUI [2]
C0232741
UMLS CUI [3]
C0232804
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
known hypersensitivity to docetaxel or taxane therapy
Description

Hypersensitivity Docetaxel | Hypersensitivity Taxane

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0246415
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0215136
documented central nervous system or leptomeningeal metastasis at time of study entry
Description

CNS metastases | Metastatic Malignant Neoplasm to the Leptomeninges

Data type

boolean

Alias
UMLS CUI [1]
C0686377
UMLS CUI [2]
C1704231
had prior treatment with chemotherapy, bone seeking radionucleides in past 6 weeks prior to enrollment, or radiotherapy involving more than 25% of marrow producing area.
Description

Prior Chemotherapy | Bone-seeking Radioisotope | Therapeutic radiology procedure Bone Marrow Percentage

Data type

boolean

Alias
UMLS CUI [1]
C1514457
UMLS CUI [2]
C2985504
UMLS CUI [3,1]
C1522449
UMLS CUI [3,2]
C0005953
UMLS CUI [3,3]
C0439165
evidence of painful and/or destructive bone metastases for which radiation therapy, biophosphonates or boneseeking radionucleides are necessary.
Description

Secondary malignant neoplasm of bone Painful | Secondary malignant neoplasm of bone Destruction | Therapeutic radiology procedure Required | Diphosphonates Required | Bone-seeking Radioisotope Required

Data type

boolean

Alias
UMLS CUI [1,1]
C0153690
UMLS CUI [1,2]
C0030193
UMLS CUI [2,1]
C0153690
UMLS CUI [2,2]
C1948029
UMLS CUI [3,1]
C1522449
UMLS CUI [3,2]
C1514873
UMLS CUI [4,1]
C0012544
UMLS CUI [4,2]
C1514873
UMLS CUI [5,1]
C2985504
UMLS CUI [5,2]
C1514873
have received treatment in the last 30 day with a drug which has not received regulatory approval for any indication at the time of study entry.
Description

Drugs, Non-Prescription

Data type

boolean

Alias
UMLS CUI [1]
C0013231
Back to the top of the page

Similar models

Eligibility Prostate Cancer NCT00642018

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Adenocarcinoma of the prostate metastatic | Adenocarcinoma of prostate unresectable
Item
histologically or cytologically confirmed adenocarcinoma of the prostate which is metastatic and/or unresectable
boolean
C0862636 (UMLS CUI [1])
C0007112 (UMLS CUI [2,1])
C1519810 (UMLS CUI [2,2])
Hormone refractory prostate cancer Progressive | Raised prostate specific antigen Quantity
Item
hormone refractory prostate cancer defined as progressive based by documented 2 increase psa values over a previous reference value.
boolean
C1328504 (UMLS CUI [1,1])
C0205329 (UMLS CUI [1,2])
C0178415 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
ECOG performance status
Item
ecog status 0-2
boolean
C1520224 (UMLS CUI [1])
Hematologic function | Liver function | Renal function
Item
adequate hematological functions, liver and renal functions
boolean
C0221130 (UMLS CUI [1])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
Hypersensitivity Docetaxel | Hypersensitivity Taxane
Item
known hypersensitivity to docetaxel or taxane therapy
boolean
C0020517 (UMLS CUI [1,1])
C0246415 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0215136 (UMLS CUI [2,2])
CNS metastases | Metastatic Malignant Neoplasm to the Leptomeninges
Item
documented central nervous system or leptomeningeal metastasis at time of study entry
boolean
C0686377 (UMLS CUI [1])
C1704231 (UMLS CUI [2])
Prior Chemotherapy | Bone-seeking Radioisotope | Therapeutic radiology procedure Bone Marrow Percentage
Item
had prior treatment with chemotherapy, bone seeking radionucleides in past 6 weeks prior to enrollment, or radiotherapy involving more than 25% of marrow producing area.
boolean
C1514457 (UMLS CUI [1])
C2985504 (UMLS CUI [2])
C1522449 (UMLS CUI [3,1])
C0005953 (UMLS CUI [3,2])
C0439165 (UMLS CUI [3,3])
Secondary malignant neoplasm of bone Painful | Secondary malignant neoplasm of bone Destruction | Therapeutic radiology procedure Required | Diphosphonates Required | Bone-seeking Radioisotope Required
Item
evidence of painful and/or destructive bone metastases for which radiation therapy, biophosphonates or boneseeking radionucleides are necessary.
boolean
C0153690 (UMLS CUI [1,1])
C0030193 (UMLS CUI [1,2])
C0153690 (UMLS CUI [2,1])
C1948029 (UMLS CUI [2,2])
C1522449 (UMLS CUI [3,1])
C1514873 (UMLS CUI [3,2])
C0012544 (UMLS CUI [4,1])
C1514873 (UMLS CUI [4,2])
C2985504 (UMLS CUI [5,1])
C1514873 (UMLS CUI [5,2])
Drugs, Non-Prescription
Item
have received treatment in the last 30 day with a drug which has not received regulatory approval for any indication at the time of study entry.
boolean
C0013231 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial